Familial Hypercholesterolemia (FH) Drugs Market, Market Insights and Treatment

September 25 13:42 2020
Familial Hypercholesterolemia (FH) Drugs Market, Market Insights and Treatment

(Albany, US) DelveInsight has launched a new report on Familial Hypercholesterolemia Market

DelveInsight’s ‘Familial Hypercholesterolemia (FH) -Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the Familial Hypercholesterolemia (FH), historical and forecasted epidemiology as well as the Familial Hypercholesterolemia (FH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Familial Hypercholesterolemia (FH) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Familial Hypercholesterolemia (FH) market size from 2017 to 2030. The report also covers current Familial Hypercholesterolemia (FH) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Familial hypercholesterolaemia (FH), is an autosomal dominant genetic disorder being characterized by the severe hypercholesterolaemia along with cholesterol deposits in tendons and premature heart disease. FH further classified into two homozygous and heterozygous forms. This specific ailment is caused by mutation in the gene for the LDL cholesterol receptor, which is involved in passing LDL from the body. It had also been observed that, the mutations in some other genes such as PCSK9 and Apolipoprotein B gene can also cause inherited high cholesterol as these all three genes are connected with each other. It is also worth mentioning here that the probability of getting affected with FH is increased due to the inheritance of a specific type of mutation in any of these three genes.

 

View Free sample page:-  https://www.delveinsight.com/sample-request/familial-hypercholesterolemia-epidemiology-forecast-report

 

Familial Hypercholesterolemia Treatment

In general, the current mainstays for the FH treatment includes Statins, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Niacin, recently approved standard of cares, LDL apheresis and in rare cases, liver transplantation. The current market of FH is being driven by these therapies and procedures. Statins, which are being recommended as first line pharmacologic therapeutic agents reduce cardiovascular mortality even in receptor-negative patients. A combination of lipid-modifying agents such as cholesterol absorption inhibitor ZETIA (Ezetimibe; Merck/Schering-Plough Pharmaceuticals) is being recommended as second line of therapy in cases where aggressive doses of statins does not work. WELCHOL (colesevelam hydrochloride; Daiichi Sankyo) is being recommended as a further second line treatment option to achieve therapeutic goals.

Familial Hypercholesterolemia Market

As per the estimates provided by NORD (National Organisation for Rare Disorders) the worldwide prevalence of HoFH (homozygous familial hypercholesterolaemia) across populations is generally estimated to be 1 in 160,000 to 1 in 1 million.. According to the estimates provided by National Institute for Health and Clinical Excellence, the reported prevalence of heterozygous familial hypercholesterolaemia in the UK population is estimated to be 1 in 500.

 Key players of the report

  • Genzyme
  • Aegerion Pharmaceuticals
  • Esperion Therapeutics

Familial Hypercholesterolemia Report Scope

The report covers the descriptive overview of Familial Hypercholesterolemia (FH), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.

• Comprehensive insight has been provided into the Familial Hypercholesterolemia (FH) epidemiology and treatment.

• Additionally, an all-inclusive account of both the current and emerging therapies for Familial Hypercholesterolemia (FH) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.

• A detailed review of Familial Hypercholesterolemia (FH) market; historical and forecasted is included in the report, covering the 7MM drug outreach.

• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Familial Hypercholesterolemia (FH) market.

 

Download free sample page:- https://www.delveinsight.com/sample-request/familial-hypercholesterolemia-epidemiology-forecast-report

 

Table of content

1 Key Insights

2 Familial Hypercholesterolemia Market Overview at a Glance

3 Disease Background and Overview: Familial Hypercholesterolemia (FH)

4 Diagnostic guidelines for Familial Hypercholesterolemia by the American Heart Association (AHA)

5 Diagnostic guidelines for Familial Hypercholesterolemia by the National Institute for Health and Care Excellence (NICE)

6 Recognized Establishments

7 Epidemiology and Patient Population: Key Findings

8 Country Wise-Epidemiology of Familial Hypercholesterolemia (FH)

9 Treatment

10 Treatment guidelines for Familial Hypercholesterolemia by the American Heart Association (AHA)

11 Treatment guidelines by the National Institute for Health and Care Excellence (NICE)

12 Treatment guidelines for Familial Hypercholestrolemia by the Japan Atherosclerosis Society and the Asian Pacific Society of Atherosclerosis and Vascular Diseases

13 Unmet Needs

15 Marketed Drugs

16 Emerging Drugs

17 Familial Hypercholesterolemia (FH): 7 Major Market Analysis

18 Case Reports

19 Market Drivers

20 Market Barriers

21 SWOT Analysis for Familial Hypercholesterolemia

22 Appendix

23 DelveInsight Capabilities

24 Disclaimer

25 About DelveInsight

 Why should you buy this report?

The report will help in developing business strategies by understanding trends shaping and driving the Familial Hypercholesterolemia (FH).

  • To understand the future market competition in the asprgillosis market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Familial Hypercholesterolemia (FH) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Familial Hypercholesterolemia (FH) market.
  • To understand the future market competition in the Familial Hypercholesterolemia (FH) market.

Related Reports

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

  Categories: